[1] Diego HP, Almanza SL, Mehrnaz MG, et al. Nonalcoholic fatty liver disease demonstrates a pre-fibrotic and premalignant molecular signature. Dig Dis Sci, 2019,64(5):1257-1269. [2] Kim N H, Jung Y S, Hong H P, et al. Association between cotinine-verified smoking status and risk of nonalcoholic fatty liver disease. Liver Int, 2018,38(8):1487-1494. [3] Koh Z J, Salgaonkar H P, Lee W J J, et al. Improvement in non-alcoholic fatty liver disease score correlates with weight loss in obese patients undergoing laparoscopic sleeve gastrectomy: a two-centre study from an Asian cohort. Obes Surg, 2019,29(3):862-868. [4] 高慧, 匡哲, 钟春秀,等.接受抗病毒治疗的慢性乙型肝炎患者非酒精性脂肪性肝病的患病率及其危险因素分析.中华肝脏病杂志, 2019,27(5):347-351. [5] Lavine J E, Schwimmer J B, Natta M L V, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2018,305(16):1659-1668. [6] Barritt A S, Gitlin N, Klein S, et al. Design and rationale for a real-world observational cohort of patients with nonalcoholic fatty liver disease: The TARGET-NASH study. Contemp Clin Trials, 2017, 61(10):33-38. [7] Chávez-Talavera O, Tailleux A, Lefebvre P, et al. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liver disease. Gastroenterology, 2017, 152(7):1679-1694. [8] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会, 范建高,等.非酒精性脂肪性肝病防治指南(2018年更新版).实用肝脏病杂志,2018, 21(2):30-39. [9] Parolova NI. Comparative analysis of results of breath ammonium test and C13 breathtest in diagnostic of helicobacter pylori infection. Helicobacter, 2016, 21(S1):93-93. [10] 中国中西医结合学会消化系统疾病专业委员会.非酒精性脂肪性肝病中西医结合诊疗共识意见(2017年).中国中西医结合消化杂志,2017,25(11):805-811. [11] Chaidee A, Onsurathum S, Intuyod K, et al. Opisthorchis viverrini infectionaugments the severity of nonalcoholic fatty liver disease in high-fat/high-fructose diet-fed hamsters. Am J Trop Med Hyg, 2019, 101(5):1161-1169. [12] Bugianesi E, Marietti M . Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients, 2013, 5(5):1544-1560. [13] Nádasdi Á, Somogyi A, Igaz P, et al. Non-alcoholic fatty liver disease - a summary and update based on the EASL-EASD-EASO Clinical Practice Guidelines of 2016. Orv Hetil, 2018,159(45):1815-1830. [14] Cai Y, Liang Q, Chen W, et al. Evaluation of huoxuehuayu therapy for nonalcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trial. Bmc Complement Altern Med, 2019, 19(1)178-185. [15] Saijie S, Yu C, Han F, et al. HP-beta-CD functionalized Fe3O4/CNPs-based theranostic nanoplatform for pH/NIR responsive drug release and MR/NIRFL imaging-guided synergetic chemo/photothermal therapy of tumor. ACS Appl Mater Interfaces, 2018,10(40):33867-33878. [16] Ferguson E L, Scomparin A, Hailu H, et al. HPMA copolymer-phospholipase C and dextrin-phospholipase A2 as model triggers for polymer enzyme liposome therapy (PELT). J Drug Target, 2017, 25(9-10):1-33. [17] Mantovani A, Mingolla L, Rigolon R, et al. Nonalcoholic fatty liver disease is independently associated with an increased incidence of cardiovascular disease in adult patients with type 1 diabetes. Int J Cardiol, 2016, 225(15):387-391. [18] Utzeri E, Usai P . Role of non-steroidal anti-inflammatory drugs on intestinal permeability and nonalcoholic fatty liver disease. World J Gastroentero, 2017(22):3954-3963. [19] 谢伶俐, 吴方建, 梁斌,等. 吡格列酮对合并代谢综合征的非酒精性脂肪性肝病患者血清TNF-α、IL-6的影响及意义. 中国医院药学杂志, 2016, 36(12):1007-1011. [20] Kakino S, Ohki T, Nakayama H, et al. Pivotal role of TNF-α in the development and progression of nonalcoholic fatty liver disease in a murine model. Horm Metab Res, 2017, 50(1):80-87. [21] Sarkar M, Wellons M, Cedars M I, et al. Testosterone levels in pre-menopausal women are associated with nonalcoholic fatty liver disease in midlife. Am J Gastroenterol, 2017, 112(5):755-762. [22] 徐亮, 江勇, 范建高,等.反应性氧化物,脂联素在慢性乙型肝炎病毒感染合并非酒精性脂肪性肝病中的研究.中华肝脏病杂志, 2020,28(3):247-253. [23] Dasarathy HL, Jaividhya G, Varghese A, et al. Patients with nonalcoholic fatty liver disease have a low response rate to Vitamin D supplementation. J Nutr, 2017,147(10):1938-1946. [24] Ponziani F R, Bhoori S, Castelli C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease. Hepatology, 2018, 69(1):107-120. [25] Da Silva E M, Kay A, Lobato C, et al. Non-F HBV/HDV-3 co-infection is associated with severe liver disease in western Brazilian amazon. J Med Virol, 2019,91(6):1081-1086. |